Hedgehog / Smoothened antagonist

Hedgehog/Smoothened antagonists are pharmaceutical agents that inhibit the Hedgehog signaling pathway by targeting the Smoothened receptor, a key component of this pathway. The Hedgehog pathway plays a crucial role in embryonic development, tissue regeneration, and stem cell maintenance. Dysregulation of this pathway has been implicated in various cancers, including basal cell carcinoma and medulloblastoma. Smoothened antagonists act by binding to and blocking the activity of the Smoothened receptor, thereby preventing downstream activation of Hedgehog pathway signaling. By inhibiting this pathway, these antagonists aim to reduce the proliferation and survival of cancer cells that depend on aberrant Hedgehog signaling for growth, offering potential therapeutic benefits in the treatment of Hedgehog pathway-driven cancers.